


CLAIMS

1. A compound having the formula (I):



wherein

X is selected from the radicals $-\text{NR}_1-$ and $-\text{CHR}_1-$;

Y is independently selected from O and S;

10 Z is independently selected from a C_{1-7} straight or C_{4-8} branched alkylene chain, a C_{2-7} alkenylene chain and a part of a C_{3-8} cycloalkyl or C_{5-8} cykloalkenyl ring structure;

Ar is an aryl group selected from aromatic carbocyclic ring systems, five- or six-membered heteroaromatic ring systems and bicyclic heteroaromatic ring systems;

R_1 , R_2 and R_3 are independently selected from a group of substituents (a)-(d) consisting of:

- (a) H;
- 20 (b) C_{1-6} straight or C_{4-8} branched chain alkyl;
- (c) C_{3-8} cycloalkyl or C_{5-8} cykloalkenyl; and
- (d) C_{2-6} alkenyl or alkynyl;

wherein the substituents (b)-(d) optionally have at least one substituent independently selected from a group

25 (e)-(i) consisting of:

- (e) Ar, O-Ar or S-Ar;
- (f) OH, O-alkyl or S-alkyl, where alkyl is selected from the substituents (b)-(c);
- (g) NR_4R_5 , where R_4 and R_5 are independently selected from the substituents (a)-(d) or optionally together form a nitrogen containing ring structure comprising from 2 to 5 carbon atoms;
- 30 (h) $\text{NH}-\text{C}(\text{O})$ -alkyl, $\text{C}(\text{O})$ -alkyl, $\text{O}-\text{C}(\text{O})$ -alkyl or S-

C(O)-alkyl, where alkyl is selected from the substituents (b)-(c); and

(i) F, Cl or Br;

R₆ is selected from a group consisting of Ar and the substituents (a)-(c), where (b) and (c) are optionally substituted with at least one of the substituents (e)-(i); Ar optionally has at least one substituent independently selected from the substituents (b)-(i); and tautomers, solvates and pharmaceutically acceptable salts of said compound.

2. A compound according to claim 1, wherein X is a radical -NR₁-.

3. A compound according to claim 2, wherein R₁ is H.

4. A compound according to any one of claims 1-3, wherein Y is O.

5. A compound according to any one of claims 1-4, wherein Ar is selected from phenyl and naphthyl.

6. A compound according to any one of claims 1-5, wherein Z is selected from -CH₂-, -(CH₂)₂-, -(CH₂)₃-, -(CH₂)₅-, -(CH₂)₆-, -(CH₂)₇- and trans-2-cyclohexylene.

7. A compound according to any one of claims 1-6, wherein R₆ is selected from isopropyl, cyclopentyl, cyclohexyl, phenyl, 4-n-butylphenyl, 4-isopropylphenyl and 2-naphthyl.

8. A compound according to any one of claims 1-7, wherein R₂ and R₃ are independently selected from H and 4-chlorobenzyl.

9. A compound according to any one of claims 1-8, wherein the compound is selected from a group consisting of:

4-[3-phenyl-1-(6-phenylhexyl)ureido]butyramide;

4-[1-(4-butylbenzyl)-3-phenylureido]butyramide;

4-[1-(4-isopropylbenzyl)-3-phenylureido]butyramide;

4-[1-(4-methylpentyl)-3-phenylureido]butyramide;

N-(4-chlorobenzyl)-4-[1-(3-cyclohexylpropyl)-3-phenylureido]butyramide;

trans-2-[1-(3-cyclohexylpropyl)-3-phenylureido]cyclohexanecarboxamide;

4-[1-(3-cyclohexylpropyl)-3-naphthalen-2-yl-ureido]-butyramide;

5 4-[1-(2-naphthalen-2-yl-ethyl)-3-phenylureido]butyramide;

4-[1-(2-cyclohexylethyl)-3-phenylureido]butyramide;

4-(1-phenethyl-3-phenylureido)butyramide;

4-(1-benzyl-3-phenylureido)butyramide;

4-[1-(3-cyclopentylpropyl)-3-phenylureido]butyramide;

10 4-[3-phenyl-1-(5-phenylpentyl)ureido]butyramide; and

4-[1-(3-cyclohexylpropyl)-3-phenylureido]butyramide.

10. A compound according to claim 1, wherein X is a radical -CHR₁-.

11. A compound according to claim 10, wherein said
15 radical -CHR₁- is selected from -CH₂- and (R)-CH(CH₃)-.

12. A compound according to any one of claims 10-11, wherein Y, Z, Ar, R₂, R₃ and R₆ are as defined in claims 4-8.

13. A compound according to any one of claims 10-12,
20 wherein the compound is selected from a group consisting of:

(R)-4-[(3-cyclohexylpropyl)-(2-phenylpropionyl)amino]-butyramide;

4-[(3-cyclohexylpropyl)-(2-naphthalen-2-yl-acetyl)amino]-
25 butyramide; and

8-[(3-cyclohexylpropyl)-(2-naphthalen-2-yl-acetyl)amino]-octanamide.

14. A compound according to any one of claims 1-13 for use as a pharmaceutical.

30 15. A pharmaceutical composition comprising a compound according to any one of claims 1-13 as active ingredient in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

16. Use of a compound according to any one of claims
35 1-13 for the manufacture of a medicament for treatment of pain and disorders related thereto.

17. A method for treatment of pain and disorders related thereto, wherein said method comprises administering to an animal, including human, patient of a therapeutically effective amount of a compound according to any
5. one of claims 1-13.